ReviewJournal of clinical medicine2021
Current Knowledge and Future Challenges in Takotsubo Syndrome: Part 2-Treatment and Prognosis.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Takotsubo syndrome: pathophysiological insights and innovations in patient care.Nature reviews. Cardiology · 2026Review
- SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data.European heart journal. Cardiovascular pharmacotherapy · 2026Article
- Takotsubo Syndrome in 2025: Evolving Concepts in Pathophysiology, Diagnosis, and Long-Term Management.Journal of clinical medicine · 2025Review
- Long-Term Prognosis, Risk Assessment, and Management of Patients Diagnosed with Takotsubo Syndrome: A Narrative Review.Journal of personalized medicine · 2025Review
- Regional mechanical dyssynchrony and shortened systole are present in people with Takotsubo syndrome.Communications medicine · 2024Article
- Acute Heart Failure in a Young Patient Treated in ICU-Diagnostic Pitfalls.Clinics and practice · 2024Article
- Impact of intra-aortic balloon counterpulsation on all-cause mortality among patients with Takotsubo syndrome complicated by cardiogenic shock: results from the German-Italian-Spanish (GEIST) registry.European heart journal open · 2023Article
- Takotsubo Syndrome: From Bench to Bedside and Bedside to Bench.Journal of clinical medicine · 2022Article
- Differential Diagnosis between Takotsubo Syndrome and Acute Coronary Syndrome-A Prospective Analysis of Novel Cardiovascular Biomarkers for a More Selective Triage.Journal of clinical medicine · 2022Article
- Reverse Takotsubo Cardiomyopathy After Accidental Exposure to an Illicit Substance: A Case Report.Cureus · 2022Article
- Stepwise approach for diagnosis and management of Takotsubo syndrome with cardiac imaging tools.Heart failure reviews · 2022Review
- The differential diagnostic value of selected cardiovascular biomarkers in Takotsubo syndrome.Clinical research in cardiology : official journal of the German Cardiac Society · 2022Article
- "Broken Heart" and "Broken Brain": Which Connection?Cardiology research · 2022Article
- Metabolic remodeling in takotsubo syndrome.Frontiers in cardiovascular medicine · 2022Review
- Takotsubo Cardiomyopathy: Current Treatment.Journal of clinical medicine · 2021Review
- Novel Imaging and Genetic Risk Markers in Takotsubo Syndrome.Frontiers in cardiovascular medicine · 2021Review
- The Brain-Heart Link: A Case Report of a Critically Located Multiple Sclerosis Lesion in the Brainstem Leading to Recurrent Takotsubo Syndrome.Frontiers in cardiovascular medicine · 2021Article
- Analysis of Selected Cardiovascular Biomarkers in Takotsubo Cardiomyopathy and the Most Frequent Cardiomyopathies.Frontiers in cardiovascular medicine · 2021Article
- The Synergy of ADAM17-Induced Myocardial Inflammation and Metabolic Lipids Dysregulation During Acute Stress: New Pathophysiologic Insights Into Takotsubo Cardiomyopathy.Frontiers in cardiovascular medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takotsubo syndrome (TTS) represents a form of acute heart failure featured by reversible left ventricular systolic dysfunction. The management during the acute phase is mainly performed with supportive pharmacological (diuretics, ACE-inhibitors/angiotensin-receptor blockers (ARBs), anticoagulants, antiarrhythmics, non-catecholamine inotropics (levosimendan), and non-pharmacological (mechanical circulatory and respiratory support) therapy, due to the wide clinical presentation and course of the disease. However, there is a gap in evidence and there are no randomized and adequately powered studies on clinical effectiveness of therapeutic approaches. Some evidence supports the use ACE-inhibitors/ARBs at long-term. A tailored approach based on cardiovascular and non-cardiovascular risk factors is strongly suggested for long-term management. The urgent need for evidence-based treatment approaches is also reflected by the prognosis following TTS. The acute phase of the disease can be accompanied by various cardiovascular complications. In addition, long term outcome of TTS patients is also related to non-cardiovascular comorbidities. Physical triggers such as hypoxia and acute neurological disorders in TTS are associated with a poor outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.